Exciting Participation at the Global Investment Conference
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) has announced a significant presence at an upcoming global investment event. The company's CEO, Gil Efron, will engage with investors in a lively fireside chat and one-on-one meetings at the H.C. Wainwright 27th Annual Global Investment Conference. This event holds prominence in the investment world, providing an excellent platform for Purple Biotech to showcase its pioneering work.
Event Details Overview
The conference is scheduled for September 8-10, with Efron’s fireside chat taking place on Wednesday, September 10, at 11:30 AM ET. Participants can look forward to gaining insights into the company’s strategic direction and groundbreaking therapies aimed at overcoming major challenges in oncology.
Purple Biotech's Innovative Approach to Cancer Treatment
At the heart of Purple Biotech's mission is the development of first-in-class therapies designed to tackle tumor immune evasion and drug resistance. This area of study is becoming increasingly critical as cancer treatment evolves. The company’s promising oncology pipeline includes CAPTN-3, CM24, and NT219, which offer innovative solutions that could change the treatment landscape.
Advancement of CAPTN-3
One standout product is CAPTN-3, showcasing a unique preclinical platform of conditionally activated tri-specific antibodies. These antibodies engage both T cells and NK cells, working together to induce a robust immune response right within the tumor microenvironment. By confining therapeutic activity to the local area, this technology aims to improve treatment outcomes and expand the therapeutic window for patients.
CM24’s Role in Treatment
CM24 is another critical player in the company’s lineup. As a humanized monoclonal antibody that effectively blocks CEACAM1, it plays a vital role in mitigating tumor immune evasion and survival through diverse pathways. Research highlights its potential as a target for various cancer types, with a completed Phase 2 study demonstrating significant efficacy improvements when used alongside nivolumab and chemotherapy for pancreatic ductal adenocarcinoma (PDAC).
Unveiling NT219 and its Potential
Further strengthening its therapeutic portfolio, NT219 is a novel small molecule dual inhibitor targeting IRS1/2 and STAT3, which could reshape treatment options for patients suffering from recurrent and metastatic diseases. A recently launched Phase 2 study in collaboration with the University of Colorado could reinforce its effectiveness when combined with cetuximab or pembrolizumab in advanced squamous cell carcinoma of the head and neck.
Company Commitment and Goals
Purple Biotech is committed to advancing its innovative therapies to combat the challenges that cancer presents. By participating in high-profile investment conferences, the company aims to raise awareness and attract support for its groundbreaking approaches. Having corporate headquarters located in Rehovot, Israel, Purple Biotech is strategically positioned at the intersection of cutting-edge research and investment potential.
Frequently Asked Questions
What is Purple Biotech's main focus?
Purple Biotech primarily focuses on developing first-in-class therapies to counter tumor immune evasion and drug resistance, targeting critical areas in oncology.
Who is representing Purple Biotech at the conference?
The CEO, Gil Efron, will represent Purple Biotech during the H.C. Wainwright Investment Conference.
What are the key therapies Purple Biotech is developing?
The key therapies include CAPTN-3, CM24, and NT219, each targeting different aspects of tumor immune response and drug resistance.
When is the conference taking place?
The H.C. Wainwright 27th Annual Global Investment Conference is scheduled for September 8-10, with a specific presentation by Efron on September 10.
How can I learn more about Purple Biotech's research?
To learn more about Purple Biotech and their innovations, you can visit their official website.
